A gene-alteration profile of human lung cancer cell lines

Raquel Blanco, Reika Iwakawa, Moying Tang, Takashi Kohno, Barbara Angulo, Ruben Pio, Luis M. Montuenga, John D. Minna, Jun Yokota, Montse Sanchez-Cespedes

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Aberrant proteins encoded from genes altered in tumors drive cancer development and may also be therapeutic targets. Here we derived a comprehensive gene-alteration profile of lung cancer cell lines. We tested 17 genes in a panel of 88 lung cancer cell lines and found the rates of alteration to be higher than previously thought. Nearly all cells feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, MET, ERBB2, and NRAS alterations were infrequent. A preferential accumulation of alterations among histopathological types and a mutually exclusive occurrence of alterations of CDKN2A and RB1 as well as of KRAS, epidermal growth factor receptor (EGFR), NRAS, and ERBB2 were seen. Moreover, in nonsmall-cell lung cancer (NSCLC), concomitant activation of signal transduction pathways known to converge in mammalian target of rapamycin (mTOR) was common. Cells with single activation of ERBB2, PTEN, or MET signaling showed greater sensitivity to cell-growth inhibition induced by erlotinib, LY294002, and PHA665752, respectively, than did cells featuring simultaneous activation of these pathways, underlining the need for combined therapeutic strategies in targeted cancer treatments. In conclusion, our gene-alteration landscape of lung cancer cell lines provides insights into how gene alterations accumulate and biological pathways interact in cancer.

Original languageEnglish (US)
Pages (from-to)1199-1206
Number of pages8
JournalHuman Mutation
Volume30
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Lung Neoplasms
Cell Line
Genes
Neoplasms
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Sirolimus
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Signal Transduction
Therapeutics
Growth
Proteins

Keywords

  • Lung cancer
  • Oncogenes
  • Tumor suppressors
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Blanco, R., Iwakawa, R., Tang, M., Kohno, T., Angulo, B., Pio, R., ... Sanchez-Cespedes, M. (2009). A gene-alteration profile of human lung cancer cell lines. Human Mutation, 30(8), 1199-1206. https://doi.org/10.1002/humu.21028

A gene-alteration profile of human lung cancer cell lines. / Blanco, Raquel; Iwakawa, Reika; Tang, Moying; Kohno, Takashi; Angulo, Barbara; Pio, Ruben; Montuenga, Luis M.; Minna, John D.; Yokota, Jun; Sanchez-Cespedes, Montse.

In: Human Mutation, Vol. 30, No. 8, 08.2009, p. 1199-1206.

Research output: Contribution to journalArticle

Blanco, R, Iwakawa, R, Tang, M, Kohno, T, Angulo, B, Pio, R, Montuenga, LM, Minna, JD, Yokota, J & Sanchez-Cespedes, M 2009, 'A gene-alteration profile of human lung cancer cell lines', Human Mutation, vol. 30, no. 8, pp. 1199-1206. https://doi.org/10.1002/humu.21028
Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R et al. A gene-alteration profile of human lung cancer cell lines. Human Mutation. 2009 Aug;30(8):1199-1206. https://doi.org/10.1002/humu.21028
Blanco, Raquel ; Iwakawa, Reika ; Tang, Moying ; Kohno, Takashi ; Angulo, Barbara ; Pio, Ruben ; Montuenga, Luis M. ; Minna, John D. ; Yokota, Jun ; Sanchez-Cespedes, Montse. / A gene-alteration profile of human lung cancer cell lines. In: Human Mutation. 2009 ; Vol. 30, No. 8. pp. 1199-1206.
@article{b48df6c89b0e44a68b120bd134b83fca,
title = "A gene-alteration profile of human lung cancer cell lines",
abstract = "Aberrant proteins encoded from genes altered in tumors drive cancer development and may also be therapeutic targets. Here we derived a comprehensive gene-alteration profile of lung cancer cell lines. We tested 17 genes in a panel of 88 lung cancer cell lines and found the rates of alteration to be higher than previously thought. Nearly all cells feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, MET, ERBB2, and NRAS alterations were infrequent. A preferential accumulation of alterations among histopathological types and a mutually exclusive occurrence of alterations of CDKN2A and RB1 as well as of KRAS, epidermal growth factor receptor (EGFR), NRAS, and ERBB2 were seen. Moreover, in nonsmall-cell lung cancer (NSCLC), concomitant activation of signal transduction pathways known to converge in mammalian target of rapamycin (mTOR) was common. Cells with single activation of ERBB2, PTEN, or MET signaling showed greater sensitivity to cell-growth inhibition induced by erlotinib, LY294002, and PHA665752, respectively, than did cells featuring simultaneous activation of these pathways, underlining the need for combined therapeutic strategies in targeted cancer treatments. In conclusion, our gene-alteration landscape of lung cancer cell lines provides insights into how gene alterations accumulate and biological pathways interact in cancer.",
keywords = "Lung cancer, Oncogenes, Tumor suppressors, Tyrosine kinase inhibitors",
author = "Raquel Blanco and Reika Iwakawa and Moying Tang and Takashi Kohno and Barbara Angulo and Ruben Pio and Montuenga, {Luis M.} and Minna, {John D.} and Jun Yokota and Montse Sanchez-Cespedes",
year = "2009",
month = "8",
doi = "10.1002/humu.21028",
language = "English (US)",
volume = "30",
pages = "1199--1206",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - A gene-alteration profile of human lung cancer cell lines

AU - Blanco, Raquel

AU - Iwakawa, Reika

AU - Tang, Moying

AU - Kohno, Takashi

AU - Angulo, Barbara

AU - Pio, Ruben

AU - Montuenga, Luis M.

AU - Minna, John D.

AU - Yokota, Jun

AU - Sanchez-Cespedes, Montse

PY - 2009/8

Y1 - 2009/8

N2 - Aberrant proteins encoded from genes altered in tumors drive cancer development and may also be therapeutic targets. Here we derived a comprehensive gene-alteration profile of lung cancer cell lines. We tested 17 genes in a panel of 88 lung cancer cell lines and found the rates of alteration to be higher than previously thought. Nearly all cells feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, MET, ERBB2, and NRAS alterations were infrequent. A preferential accumulation of alterations among histopathological types and a mutually exclusive occurrence of alterations of CDKN2A and RB1 as well as of KRAS, epidermal growth factor receptor (EGFR), NRAS, and ERBB2 were seen. Moreover, in nonsmall-cell lung cancer (NSCLC), concomitant activation of signal transduction pathways known to converge in mammalian target of rapamycin (mTOR) was common. Cells with single activation of ERBB2, PTEN, or MET signaling showed greater sensitivity to cell-growth inhibition induced by erlotinib, LY294002, and PHA665752, respectively, than did cells featuring simultaneous activation of these pathways, underlining the need for combined therapeutic strategies in targeted cancer treatments. In conclusion, our gene-alteration landscape of lung cancer cell lines provides insights into how gene alterations accumulate and biological pathways interact in cancer.

AB - Aberrant proteins encoded from genes altered in tumors drive cancer development and may also be therapeutic targets. Here we derived a comprehensive gene-alteration profile of lung cancer cell lines. We tested 17 genes in a panel of 88 lung cancer cell lines and found the rates of alteration to be higher than previously thought. Nearly all cells feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, MET, ERBB2, and NRAS alterations were infrequent. A preferential accumulation of alterations among histopathological types and a mutually exclusive occurrence of alterations of CDKN2A and RB1 as well as of KRAS, epidermal growth factor receptor (EGFR), NRAS, and ERBB2 were seen. Moreover, in nonsmall-cell lung cancer (NSCLC), concomitant activation of signal transduction pathways known to converge in mammalian target of rapamycin (mTOR) was common. Cells with single activation of ERBB2, PTEN, or MET signaling showed greater sensitivity to cell-growth inhibition induced by erlotinib, LY294002, and PHA665752, respectively, than did cells featuring simultaneous activation of these pathways, underlining the need for combined therapeutic strategies in targeted cancer treatments. In conclusion, our gene-alteration landscape of lung cancer cell lines provides insights into how gene alterations accumulate and biological pathways interact in cancer.

KW - Lung cancer

KW - Oncogenes

KW - Tumor suppressors

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=67749108202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749108202&partnerID=8YFLogxK

U2 - 10.1002/humu.21028

DO - 10.1002/humu.21028

M3 - Article

VL - 30

SP - 1199

EP - 1206

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 8

ER -